Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported late-stage study results for its obesity drug treatment. However, the weight-loss difference of only 3.6% missed the FDA's draft standard of at least 5%. The stock price plunged $1.20 to $3.30.
Arena Misses Trial Targets
March 30, 2009 at 14:30 PM EDT
